You are here

NANOMETICS LLC

Company Information
Address
505 COAST BLVD S
LA JOLLA, CA 92037-4616
United States


http://www.phdbiosciences.com

Information

UEI: PM3SN3WEQW86

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis

    Amount: $1,000,000.00

    PROJECT SUMMARY / ABSTRACT Acinic Keratoses (AK) are premalignant skin lesions with the potential to develop into Cutaneous Squamous cell Carcinoma (CSCC), which is the second most common type of canc ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations

    Amount: $398,768.00

    PROJECT SUMMARY / ABSTRACT Problem to be Solved and Significance: Exposure to Ultraviolet radiation (UVR) is a risk factor for the development of skin cancer, and health care agencies recommend that s ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer

    Amount: $2,000,000.00

    PROJECT SUMMARY / ABSTRACT This Phase II project is predicated on the NCI Phase I award 1R43CA236265-01 and is a resubmission. Problem to be Solved and Significance: Exposure to Ultraviolet radiation ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  4. A novel small molecule Bax activator as an oral therapeutic for the treatment of lung cancer.

    Amount: $299,676.00

    PROJECT SUMMARY Problem to be SolvedLung cancerLCis the leading cause of cancer related deaths in the United StatesU Sand worldwideIna total ofmillion new cases were estimated globallyaccounting forof ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  5. The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer

    Amount: $224,831.00

    PROJECT SUMMARYABSTRACT Problem to be Solved and SignificanceExposure to Ultraviolet radiationUVRis a risk factor for the development of skin cancerand health care agencies recommend that sunscreens b ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  6. A repurposed molecule as an oral therapeutic to improve vascular flow in sickle cell disease

    Amount: $224,553.00

    PROJECT SUMMARY Problem to be SolvedSickle cell diseaseSCDis a global health issue that affects approximatelyAmericans and overmillion people worldwideAs a chronic and multifactorial diseaseit is char ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  7. A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome

    Amount: $1,999,248.00

    Problem to be SolvedCapecitabine is a widely prescribed and orally available prodrug of the chemotherapeutic agentfluorouracilFUThe principle dose schedule limiting toxicity associated with its use is ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. A targeted drug for the treatment of inflammation in cystic fibrosis lung disease

    Amount: $224,958.00

    DESCRIPTION provided by applicant Problem to be Solved Cystic fibrosis CF is a global health issue that affects over people worldwide including Americans Lung disease is the p ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  9. A targeted immunomodulator for the treatment of acute sickle crisis

    Amount: $224,901.00

    DESCRIPTION provided by applicant Sickle cell disease SCD is a global health issue that affects over million people worldwide including Americans SCD is a chronic and multifactorial ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  10. The Translational Development of a Therapeutic For Triple Negative Breast Cancer

    Amount: $1,499,919.00

    DESCRIPTION provided by applicant Triple negative breast cancer TNBC accounts for of all diagnosed breast cancers worldwide TNBC carries a poorer prognosis and lower survival rate compare ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government